Drug intelligence / Profile preview

revumenib

Development stage: Approved
Lead developer: Syndax Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Revumenib is an oral, small molecule menin inhibitor used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A, also known as MLL) rearrangements. It works by disrupting the interaction between menin and KMT2A, a protein complex that drives leukemogenesis in these cancers. By blocking this interaction, revumenib downregulates oncogenic gene expression and promotes differentiation or death of leukemia cells. The drug is indicated for relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients aged 1 year and older. Revumenib was developed by Syndax Pharmaceuticals and is marketed under the brand name Revuforj[1][4][5][6][7][8].

Brand names: Revuforj
Other names: revumenib

Targets

KMT2A

Beyond the preview

Go deeper on revumenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on revumenib.

Explore the full profile